Cg Oncology Inc (NASDAQ:CGON)’s traded shares stood at 2.15 million during the last session, with the company’s beta value hitting 1.94. At the close of trading, the stock’s price was $17.78, to imply an increase of 14.05% or $2.19 in intraday trading. The CGON share’s 52-week high remains $46.99, putting it -164.29% down since that peak but still an impressive 13.44% since price per share fell to its 52-week low of $15.39. The company has a valuation of $1.36B, with an average of 1.55 million shares in intraday trading volume over the past 10 days and average of 754.50K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cg Oncology Inc (CGON), translating to a mean rating of 1.00. Of 4 analyst(s) looking at the stock, 0 analyst(s) give CGON a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.28.
Cg Oncology Inc (NASDAQ:CGON) trade information
After registering a 14.05% upside in the last session, Cg Oncology Inc (CGON) has traded red over the past five days. The 5-day price performance for the stock is -20.05%, and -32.40% over 30 days. With these gigs, the year-to-date price performance is -38.01%. Short interest in Cg Oncology Inc (NASDAQ:CGON) saw shorts transact 7.23 million shares and set a 11.7 days time to cover.
The extremes give us $55 and $60 for target low and target high price respectively. As such, CGON has been trading -237.46% off suggested target high and -209.34% from its likely low.
Cg Oncology Inc (CGON) estimates and forecasts
The rating firms project that company’s revenue will grow 203.77% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 144.61k. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 148.78k.Earnings reports from the last fiscal year show that sales brought in 529k and 111k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -72.66% before jumping 34.04% in the following quarter.
CGON Dividends
Cg Oncology Inc has its next earnings report out on 2025-Mar-27. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Cg Oncology Inc (NASDAQ:CGON)’s Major holders
Cg Oncology Inc insiders hold 6.16% of total outstanding shares, with institutional holders owning 98.32% of the shares at 104.77% float percentage. In total, 98.32% institutions holds shares in the company, led by DECHENG CAPITAL LLC. As of 2024-06-30, the company held over 5.46 million shares (or 8.1903% of shares), all amounting to roughly $172.33 million.
The next major institution holding the largest number of shares is TCG CROSSOVER MANAGEMENT, LLC with 3.67 million shares, or about 5.5067% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $115.87 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund as the top two Mutual Funds with the largest holdings of the Cg Oncology Inc (CGON) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 1.89 shares. This is just over 2.48% of the total shares, with a market valuation of $33.54 million. Data from the same date shows that the other fund manager holds a little less at 1.56, or 2.05% of the shares, all valued at about 27.74 million.
